Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
13 októbra, 2020 5:56 pmAuthor(s): Paolo Strati, Guillermo Garcia-Manero, Tapan Kadia, et al. Abstract: PS1251 Session topic: 10. Myelodysplastic syndromes – Clinical...
DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION
13 októbra, 2020 5:56 pmAuthor(s): Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, et al. Abstract: PF496 Session topic: 10. Myelodysplastic syndromes –...
SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT
13 októbra, 2020 5:56 pmAuthor(s): Carolina Lazzarino, Marcelo Iastrebner, Jacqueline Gonzalez, et al. Abstract: PS1259 Session topic: 10. Myelodysplastic syndromes – Clinical...
MYELODYSPLASTICKÝ SYNDROM – VÝBĚR Z EDUKAČNÍCH SDĚLENÍ A POSTERŮ
13 októbra, 2020 5:56 pmPráce publikované formou edukačních sdělení 1. FACING THE CHALLENGE: NOVEL TREATMENT OPTIONS FOR PATIENTS WITH MYELODYSPLASTIC SYNDROMES Nové...
AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES BY PRIOR LINES OF THERAPY IN ZUMA-1
13 októbra, 2020 5:56 pmAuthor(s): Frederick L. Locke, Armin Ghobadi, Lazaros J. Lekakis, et al. Abstract: S801 Session topic: 21. Aggressive Non-Hodgkin...
AN UPDATED ANALYSIS OF JULIET, A GLOBAL PIVOTAL PHASE 2 TRIAL OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
13 októbra, 2020 5:56 pmAuthor(s): Peter Borchmann, Constantine S. Tam, Ulrich Jäger Abstract: S799 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical...
RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Frank Morschhauser, Nathan H. Fowler, Pierre Feugier, et. al Abstract: S154 Session topic: 20. Indolent Non-Hodgkin lymphoma...
ADDING POLATUZUMAB VEDOTIN (POLA) TO BENDAMUSTINE AND RITUXIMAB (BR) TREATMENT IMPROVES SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: RESULTS OF A PHASE 2 CLINICAL TRIAL
13 októbra, 2020 5:56 pmAuthor(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin...
FINAL ANALYSIS OF THE AHL201 RANDOMIZED PHASE III LYSA STUDY COMPARING AN EARLY PET DRIVEN TREATMENT DE-ESCALATION TO A NOT PET-MONITORED STRATEGY IN PATIENTS WITH ADVANCED STAGES HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Olivier Casasnovas, Pauline Brice, Reda Bouabdallah, et. al Abstract: S110 Session topic: 17. Hodgkin lymphoma – Clinical...
PRETREATMENT VITAMIN D DEFICIENCY IS ASSOCIATED WITH LOWER PROGRESSION- -FREE AND OVERALL SURVIVAL IN PROSPECTIVELY TREATED HODGKIN LYMPHOMA
13 októbra, 2020 5:56 pmAuthor(s): Sven Borchmann, Helen Görgen, Stephanie Sasse, et al. Abstract: S111 Session topic: 17. Hodgkin lymphoma – Clinical...